Optimi Health To Host MDMA Educational Quality Assurance Webinar For Clinicians And Practitioners
February 06, 2024 07:30 ET
|
Optimi Health Corp.
Highlights: Optimi Chief Science and Quality Assurance experts to provide in-depth access into the Company’s safety and quality standards.Optimi experts will address critical inquiries which still...
Optimi Health Secures Amendment to Increase Quantities Of MDMA, MDA, And 2C-B Under Controlled Drugs And Substances Dealer’s Licence
January 19, 2024 07:30 ET
|
Optimi Health Corp.
Optimi Health granted amendment to its Health Canada Controlled Drugs and Substances Licence.
Optimi Health Granted Precursor Licence To Formulate MDMA And Completes Encapsulation Of 40mg And 60mg Dosage Formats
January 03, 2024 07:30 ET
|
Optimi Health Corp.
Optimi Health Granted Precursor Licence for 3,4-Methylenedioxyphenyl-2-propanone (“MDP2P”), the precursor used in the chemical synthesis of MDMA.
Optimi Health Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing
November 28, 2023 07:42 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading end-to-end drug researcher and formulator licensed by Health...
Optimi Health Resolves Dispute
November 10, 2023 07:30 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company") is pleased to announce the successful resolution...
Optimi Health Welcomes Dr. Preston A. Chase as New Chief Science Officer
November 07, 2023 07:30 ET
|
Optimi Health Corp.
Optimi Health Introduces New Chief Science Officer Dr. Preston A. Chase.
Optimi Health Announces Third and Final Tranche of CAD $1,000,000 Secured for Debt Financing
November 02, 2023 07:30 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi Health” or the “Company”), a Canadian drug research and formulation...
Optimi Health Granted Amendment to Dealer's Licence by Health Canada to Supply Special Access Program
September 07, 2023 07:30 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, proudly...
Optimi Health Announces Second Tranche of CAD $1,000,000 Secured for Debt Financing
September 05, 2023 07:30 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi Health” or the “Company”), a Canadian drug research and formulation...
Optimi Completes Proprietary Natural Psilocybin Extraction Process and Files U.S. Provisional Patent
August 01, 2023 07:30 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator...